Table 3

Cox regression analysis examining the relation of proteins with incident atrial fibrillation

HR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P value
Model 1Model 2Model 3
NT-proBNP1.95 (1.75 to 2.19)5.1×10–321.80 (1.60 to 2.04)3.2×10–211.80 (1.58 to 2.04)1.2×10–19
OPN1.38 (1.22 to 1.56)4.2×10–71.27 (1.12 to 1.44)2.2×10–41.27 (1.12 to 1.44)2.7×10–4
MMP-21.29 (1.14 to 1.47)6.6×10–51.20 (1.21 to 1.84)0.0041.22 (1.07 to 1.39)0.002
IGFBP-71.27 (1.12 to 1.43)1.2×10–41.18 (1.05 to 1.33)0.0071.15 (1.02 to 1.29)0.026
UPAR1.30 (1.15 to 1.47)3.7×10–51.20 (1.05 to 1.36)0.0061.16 (1.02 to 1.32)0.028
FABP41.27 (1.13 to 1.44)8.6×10–51.36 (1.19 to 1.55)9.0×10–61.14 (0.98 to 1.32)0.098
GDF-151.41 (1.25 to 1.59)9.7×10–91.22 (1.07 to 1.38)0.0031.141 (0.97 to 1.27)0.126
GAL-41.30 (1.15 to 1.47)3.5×10–51.21 (1.07 to 1.37)0.0031.09 (0.95 to 1.24)0.220
CHI3L11.26 (1.12 to 1.43)1.4×10–41.15 (1.02 to 1.30)0.0211.07 (0.95 to 1.22)0.257
TNFR11.26 (1.12 to 1.42)1.6×10–41.14 (1.01 to 1.29)0.0351.07 (0.94 to 1.21)0.297
PON30.80 (0.72 to 0.89)7.3×10–50.82 (0.73 to 0.92)0.0010.94 (0.83 to 1.11)0.298
  • Values are HRs and 95% CI for incident atrial fibrillation. Model 1 is unadjusted. Model 2 is age and sex adjusted. Model 3 is further adjusted for body mass index, systolic blood pressure, smoking status, prevalent diabetes mellitus, prevalent coronary events, prevalent heart failure and antihypertensive treatment.

  • CHI3L1, chitinase-3-like protein 1; FABP4, fatty-acid binding protein 4; GAL-4, galectin 4; GDF-15, growth differentiation factor 15; IGFBP-7, insulin-like growth factor-binding protein 7; MMP-2, matrix metalloproteinase-2; NT-proBNP, N-terminal pro-B-type natriuretic peptide; OPN, osteopontin; PON3, paraoxonase 3; TNFR1, tumour necrosis factor receptor 1; UPAR, urokinase receptor.